ABN/ARSN

Rule 3.8A

Appendix 3E

Daily share buy-back notice (except minimum holding buy-back and selective buy-back)

Information and documents given to ASX become ASX's property and may be made public.

Name of entity

	na Pharmaceuticais Limited	15 088 417 403	
We	(the entity) give ASX the following	ng information.	
Inf	ormation about buy-back		
1	Type of buy-back	On-market buy-back	
2	Date Appendix 3C was given to ASXo	13 September 2012	
	tal of all shares/units be eptances have been recei	•	
		Before previous day	Previous day
3	Number of shares/units bought back or if buy-back is an equal access scheme, in relation to which acceptances have been received	54,455,590	530,083
4	Total consideration paid or	\$39,253,796	\$421,045
•	payable for the shares/units		

5

	Before previous			Previous day	
	day				
If buy-back is an on-market buy-back	Highest \$0.8525	price	paid:	Highest price paid: \$0.8000	
	Lowoot	prios poid		Lowest price paid: \$0.7750	
	\$0.6250	price	price paid:	Highest price allowed under rule 7.33: \$0.8190	

How many shares/units may still be bought back?

6	If the company/trust has	63,644,679
	disclosed an intention to buy	
	back a maximum number of	
	shares/units - the remaining	
	number of shares/units to be	
	bought back	
	-	

Compliance statement

- 1. The company is in compliance with all Corporations Act requirements relevant to this buy-back.
- 2. There is no information that the listing rules require to be disclosed that has not already been disclosed, or is not contained in, or attached to, this form.

or, for trusts only:

- 1. The trust is in compliance with all requirements of the Corporations Act as modified by Class Order 07/422, and of the trust's constitution, relevant to this buy-back.
- 2. There is no information that the listing rules require to be disclosed that has not already been disclosed, or is not contained in, or attached to, this form.

Sign here:

(-)

(Director/Company secretary)

Print name: SUE MORGAN

== == == ==

Date: 13 June 2013